Drug Profile
Research programme: anti-infectives - Kemin
Alternative Names: KPE 00001048; KPE 00001125; KPE 01001001; KPE 01001014; KPE00000297; KPE00000313; KPE03003015; KPE03003017; KPE03003028; KPE05001Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kemin Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Belgium
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Belgium
- 23 Sep 2008 Preclinical development is ongoing in Belgium